Thesis (Ph. D.)--University of Adelaide, Dept. of Paediatrics, 1994. / Errata slip inserted at back. Includes bibliographical references (leaves 159-192).

Thesis (M.S.)--Brandeis University, 2009. / Title from PDF title page (viewed on May 29, 2009). Includes bibliographical references.

Edited by Samuel S. Epstein, with associate editors: Joshua Lederberg [and others] / "Based on a symposium cosponsored by the Center for Studies of Narcotic and Drug Abuse, NIMH, and by the Environmental Mutagen Society, San Francisco, October 29 and 30, 1969." / Includes bibliographies.

Made available in DSpace on 2015-12-10T14:23:07Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-02-25. Added 1 bitstream(s) on 2015-12-10T14:29:22Z : No. of bitstreams: 1 000847907.pdf: 435955 bytes, checksum: 28562835fdb8912e96dfb94f7a160314 (MD5) / Introdução: A infertilidade é definida como a incapacidade de um casal obter uma gravidez ou parto de um bebê vivo. Ela não é exclusiva da mulher, mas sim do casal, e os fatores mais comuns associados são de origem genética, como alterações dos cromossomos, incluindo também causas hormonais, anatômicas, infecciosas, imunológicas, entre outras. A definição dos tipos de alterações cromossômicas presentes em um casal com dificuldades reprodutivas é de fundamental importância para sua vida reprodutiva. Objetivo: Verificar a importância das diferentes alterações cromossômicas na etiologia da infertilidade e discutir a indicação do cariótipo nos casos de dificuldades reprodutivas. Metodologia: Estudo retrospectivo de dados de 832 indivíduos, atendidos na Faculdade de Ciências/ UNESP, Bauru, no período de Janeiro de 2005 a Dezembro de 2012, referentes a estudos cromossômicos (cariótipo de sangue periférico e abortos espontâneos) e anamnese. Resultados: Dos 832 casos, 431 foram avaliados através dos cariótipos de sangue periférico e 514 através de seus cariótipos de abortos espontâneos; 113 foram avaliados tanto pelos cariótipos de sangue como pelos cariótipos de seus abortos. A frequência das alterações cromossômicas em sangue periférico foi de 5,6%, e de 32,5 % em abortos espontâneos. Não houve correlação estatística entre ocorrência das alterações cromossômicas, sexo, idade e número de abortos. Conclusões: Na população estudada observou-se que as alterações cromossômicas são importantes na etiologia da infertilidade. As alterações cromossômicas numéricas nos abortos são as mais frequentes; contudo, sua ocorrência pode ser maior devido a possível superestimação dos cariótipos normais pela contaminação de material materno. Para prevenção de malformações congênitas, ambos os membros do casal relacionados a problemas reprodutivos devem realizar o estudo cromossômico / Introduction: Infertility is defined as the inability of a couple of getting pregnant or give birth to a live baby. It is not only related to women, but also to the couple, and the most common factors associated are genetic, such as chromosome abnormalities as well as hormonal, anatomical, infectious and immunological causes, among others. The definition of the types of chromosomal abnormalities present in a couple with reproductive difficulties is of fundamental importance to their reproductive life. Objective: To assess the importance of different chromosomal abnormalities in the etiology of infertility and discuss the indication of the karyotype in cases of reproductive difficulties. Methodology: Karyotypes of peripheral blood and miscarriages (Chromosomal studies) and anamnesis of 832 individuals attended at the Faculdade de Ciências/ UNESP, Bauru, from January 2005 to December 2012 were assessed retrospectively. Results: Of the 832 cases, 431 were evaluated by peripheral blood karyotypes and 514 through their karyotypes of miscarriages; 113 were evaluated both by karyotypes of both blood and abortions. The frequency of chromosomal abnormalities in peripheral blood was 5.6%, and 32.5% in spontaneous abortions. There was no statistical correlation between occurrence of chromosomal abnormalities, sex, age and number of abortions. Conclusions: Chromosomal abnormalities are important in the etiology of infertility within the population studied. The numerical chromosomal abnormalities in abortions were the most common; however, its occurrence may be higher due to possible overestimation of normal karyotypes by contamination of maternal material. Aiming the prevention of congenital malformations, both couple members presenting reproductive problems should perform a chromosome study

Made available in DSpace on 2014-06-11T19:32:14Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-03-21Bitstream added on 2014-06-13T21:03:45Z : No. of bitstreams: 1 domingues_cef_dr_botib.pdf: 8383595 bytes, checksum: 12825237e7433888847a69be2e9616ba (MD5) / A gagueira é uma doença comum que afeta a fluência da fala, caracterizada por repetições ou prolongamentos frequentes de sons, sílaba, palavras, ou por hesitações, ou interrupções no fluxo normal da fala. Trata-se de uma doença que tipicamente surge na infância em crianças com idade entre dois e quatro anos, com taxa de incidência estimada em torno de 5% da população. No entanto devido à elevada taxa de recuperação espontânea, estima-se uma prevalência de 1% na população em geral. Apesar do envolvimento de fatores ambientais, o fator genético é determinante para o desenvolvimento da doença. Algumas evidências que sustentam essa relação são: agregação familial, estudos com gêmeos e envolvendo adoções e, relações de consanguinidade em famílias com diversos afetados. Entretanto, trata-se de uma doença complexa na qual a identificação exata do tipo de herança é difícil de ser determinada uma vez que não seguem as leis de Mendel. Este estudo teve como principal finalidade realizar análises de ligação em 43 famílias brasileiras do Estado de São Paulo, não relacionadas, portadoras de gagueira desenvolvimental persistente a fim de identificar regiões cromossômicas com possíveis genes candidatos; Para as análises de ligação, inicialmente foi realizada a genotipagem de todas as famílias através de chips específicos para essa finalidade contendo 6056 marcadores SNP. Posteriormente, para o refinamento do mapa de ligação foram utilizados marcadores microssatélites polimórficos marcados com fluoróforos e analisados em sequenciador automático capilar. Para as estimativas das frequências alélicas destes marcadores na população brasileira foram utilizados amostras do grupo controle, não relacionadas, previamente selecionadas. Apenas duas famílias (BRPD_47 e BRPD_50) sob o padrão de herança dominante... / Stuttering is a common disease that affects the fluency of speech, and is characterized by frequent repetitions or prolongations of sounds, syllables, or words, or by interruptions in the normal flow of speech. The disorder typically begins in children aged two to four years, and has an estimated incidence rate of around 5% of the population. Due to the high rate of spontaneous recovery, the estimated prevalence of the disorder is 1% in the general population. Despite the involvement of environmental factors, genetic factors have been shown to be critical to the development of the disease. Evidence supporting genetic factors include twin studies, adoption studies, family clusters of stuttering, and consanguineous relations in families with many cases of the disorder. However stuttering is a complex disorder in which the identification of the exact type of inheritance is difficult to determine because it does not follow Mendelian laws. The main goal of this study was to perform a genome-wide linkage analysis in 43 unrelated families from the Brazilian state of São Paulo, which had multiple cases of persistent developmental stuttering, in an effort to identify chromosomal regions containing possible causal genes, Linkage analysis was initially performed by genotyping of all families with chip-based methods that assayed 6056 sNP markers. Subsequent refinement of linkage locations used polymorphic microsatellite markers analyzed by capillary electrophoresis unsing an automated DNA sequencer. Unrelated normal Brazilian samples were used as a control group to estimate the allele frequencies of these markers in this population. Two families (BRPD_47 and BRPD_50) showed significant evidence for linkage in the region of chromosome 10q21 under a dominant inheritance model. Combining these two families produced... (Complete abstract click electronic access below)

M.Comm. / A revolution in genetic research, known as the Human Genome Project (HGP), is taking place. This project, initiated in 1984, is a twenty-year, six billion-dollar science project designed to map the entire genetic structure (Genome) of the human species (Brockett and Tankersley, 1995). In 1998, the HGP leaders expected to complete the project by 2003 (Lowden, J. A., 1999:33). The Human Genome Project is designed to sequence the human genome (the blue print of genetic information) and to identify the estimated 100000 genesherein. This has added a new dimension to the technology available to underwriters in the life and health insurance industry for the selection of medical risks. Genetic testing can identify inherited diseases and predict illnesses that might not manifest for decades (Brackenridge & Elder, 1998:89). Genome research has opened up new opportunities for diagnosis and in some cases, early treatment of medical conditions. This new basis of knowledge is referred to as the advent of the molecular age in medicine. Medical journals, the mass media and genetic interest groups are treating human genetics and the opportunities it presents as a high-profile issue, with great attention being paid to the complex and emotive topics of life insurance and genetic testing (Regenauer & Schmidtke, 1998:5). The Insurance Industry can use genetic testing to identify high-risk applicants more accurately and price products accordingly, thereby improving risk assessment and profitability. These potential advantages, however, are counter-balanced by ethical considerations that are much more difficult to address (Lowden, J. A., 1999:33). Many consumers, ethicists and geneticists fear that insurers will use this data for unfair discriminatory purposes, identifying a genetic underclass of people who, although clinically well, will be uninsurable. Genetic testing could invade the privacy of applicants and their families. There are concerns about the confidential handling of genetic information as well as the accurate interpretation of genetic tests. The uncertainty about the predictive value of genetic tests, the shortage of trained geneticists and counsellors and the psychological impact of that knowledge of a predictable serious disease might have, have lead to much opposition to the use of genetic information by third parties. In the United States most Americans receive health insurance through their place of employment. There are fears that genetic testing will be used to discriminate against prospective employees and render many people unemployable and uninsurable (Council for responsible Genetics, 1997: http://www.gene-watch.org/genclisc htuil Consumer groups have lobbied effectively for the prohibition of testing or the use of testing by insurers in the United States and Europe and legislators aim to ban the use of genetic information on a broad basis. Insurers, on the other hand, are assuming that the new laws will cause untold damage to the fiscal stability of their companies (Lowden, J. A., 1999:33). However, it seems inevitable that genetic testing will affect risk classification sooner rather than later and to a greater extent than most believe (Chambers, 1997: http://www.Inrc.com/epirr/issues/143/143-4.htm).

Lam, Yuk Man. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2010. / Includes bibliographical references (leaves 142-157). / Abstracts in English and Chinese. / ABSTRACT --- p.i / 摘要 --- p.iv / ACKNOWLEDGEMENTS --- p.vi / CONTRIBUTORS --- p.viii / PUBLICATIONS --- p.ix / LIST OF TABLES --- p.x / LIST OF FIGURES --- p.xi / LIST OF ABBREVIATIONS --- p.xiii / TABLE OF CONTENTS --- p.xiv / Chapter SECTION I: --- BACKGROUND --- p.1 / Chapter CHAPTER 1: --- PRENATAL DIAGNOSIS OF FETAL ANEUPLOIDIES --- p.2 / Chapter 1.1 --- The need for prenatal screening and diagnosis --- p.2 / Chapter 1.2 --- Patau Syndrome (Trisomy 13) --- p.2 / Chapter 1.3 --- Current methods for fetal aneuploidy detection --- p.4 / Chapter 1.3.1 --- Routine prenatal screening tests --- p.4 / Chapter 1.3.2 --- Definitive prenatal diagnosis by invasive procedures --- p.7 / Chapter 1.4 --- New approach for noninvasive prenatal diagnosis --- p.11 / Chapter 1.4.1 --- Circulating fetal cells --- p.11 / Chapter 1.4.2 --- Cell-free fetal nucleic acids in maternal circulation --- p.12 / Chapter 1.4.3 --- Diagnostic applications of cell-free fetal nucleic acids in maternal plasma --- p.12 / Chapter CHAPTER 2: --- DEVELOPMENT OF FETAL EPIGENETIC MARKERS IN MATERNAL PLASMA --- p.17 / Chapter 2.1 --- Limitations of fetal DNA markers --- p.17 / Chapter 2.2 --- DNA methylation is an actively-researched area under the field of epigenetics --- p.18 / Chapter 2.3 --- Genome-scale DNA methylation analysis brings new insight into epigenetics --- p.20 / Chapter 2.4 --- The first demonstration of using an epigenetic method for detecting maternally-inherited fetal DNA in maternal plasma --- p.22 / Chapter 2.5 --- The first universal marker for fetal DNA in maternal plasma --- p.24 / Chapter 2.6 --- Discovery of more fetal epigenetic markers --- p.25 / Chapter 2.6.1 --- Methylated fetal epigenetic markers are more desirable --- p.25 / Chapter 2.6.2 --- Discovery of hypermethylated fetal epigenetic markers by studying tumor suppressor genes --- p.26 / Chapter 2.6.3 --- Discovery of hypermethylated fetal epigenetic markers on chromosome 21 --- p.28 / Chapter 2.7 --- Noninvasive detection of fetal aneuploidies using fetal epigenetic markers --- p.29 / Chapter 2.7.1 --- Noninvasive detection of fetal trisomy 18 by the epigenetic allelic ratio (EAR) approach --- p.29 / Chapter 2.7.2 --- Noninvasive detection of fetal trisomy 21 by the epigenetic-genetic (EGG) approach --- p.30 / Chapter 2.8 --- Aim of thesis --- p.32 / Chapter SECTION II: --- MATERIALS AND METHODS --- p.34 / Chapter CHAPTER 3: --- METHODS FOR QUANTITATIVE ANALYSIS OF DNA METHYLATION --- p.35 / Chapter 3.1 --- Subject recruitment and sample collection --- p.35 / Chapter 3.2 --- Sample processing --- p.38 / Chapter 3.3 --- DNA extraction --- p.38 / Chapter 3.3.1 --- Placental tissues --- p.38 / Chapter 3.3.2 --- Maternal blood cells --- p.39 / Chapter 3.3.3 --- Maternal plasma --- p.40 / Chapter 3.4 --- Methylated DNA immunoprecipitation and tiling array analysis (MeDIP-chip) --- p.41 / Chapter 3.4.1 --- Principles --- p.41 / Chapter 3.4.2 --- DNA sample and array processing --- p.43 / Chapter 3.4.2.1 --- DNA preparation and target hybridization --- p.43 / Chapter 3.4.2.2 --- Data analysis --- p.44 / Chapter 3.5 --- DNA methylation analysis on randomly-chosen regions on chromosome / Chapter 3.6 --- Bisulfite conversion --- p.46 / Chapter 3.6.1 --- Principles of bisulfite conversion --- p.46 / Chapter 3.6.2 --- Procedures of bisulfite conversion --- p.46 / Chapter 3.7 --- Quantitative analysis of DNA methylation --- p.47 / Chapter 3.7.1 --- Bisulfite PCR and genomic sequencing --- p.47 / Chapter 3.7.1.1 --- Primer design for bisulfite polymerase chain reaction (PCR) --- p.47 / Chapter 3.7.1.2 --- Bisulfite PCR --- p.49 / Chapter 3.7.1.3 --- Cloning --- p.50 / Chapter 3.7.1.4 --- Bisulfite genomic sequencing --- p.52 / Chapter 3.7.1.5 --- Data acquisition and interpretation --- p.53 / Chapter 3.7.2 --- EpiTYPER，a mass-spectrometry-based method --- p.54 / Chapter 3.7.2.1 --- Principles of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) --- p.54 / Chapter 3.7.2.2 --- Primer design of the EpiTYPER assay --- p.55 / Chapter 3.7.2.3 --- The EpiTYPER assay and its principle --- p.56 / Chapter 3.8 --- Methylation-sensitive restriction enzyme (MSRE)-mediated real-time quantitative PCR (qPCR) --- p.61 / Chapter 3.9 --- Digital PCR --- p.66 / Chapter 3.9.1 --- Principles of digital PCR --- p.66 / Chapter 3.9.2 --- Poisson distribution --- p.68 / Chapter 3.10 --- Statistical analyses --- p.69 / Chapter SECTION III: --- SYSTEMATIC IDENTIFICATION OF A FETAL DNA METHYLATION MARKER ON CHROMOSOME 13 FOR DETECTION OF FETAL TRISOMY 13 --- p.70 / Chapter CHAPTER 4: --- SYSTEMATIC IDENTIFICATION OF POTENTIAL FETAL EPIGENETIC MARKERS BY MEDIP-CHIP ANALYSIS --- p.71 / Chapter 4.1 --- Systematic discovery of fetal epigenetic markers on chromosome 13 by MeDIP-chip analysis --- p.71 / Chapter 4.2 --- Experimental design --- p.73 / Chapter 4.3 --- Results --- p.76 / Chapter 4.3.1 --- Identification of differentially methylated DNA regions by MeDIP-chip or non-MeDIP-chip approaches followed by EpiTYPER analysis --- p.76 / Chapter 4.3.2 --- Confirmation of differential methylation patterns and exclusion of regions with high inter-individual variations by EpiTYPER analysis --- p.82 / Chapter 4.3.3 --- Confirmation of differential DNA methylation patterns with higher resolution by bisulfite sequencing --- p.85 / Chapter 4.4 --- Discussion --- p.95 / Chapter CHAPTER 5: --- THE APPLICATION OF FETAL EPIGENETIC MARKER ON CHROMSOME 13 FOR DETECTION OF FETAL TRISOMY 13 --- p.98 / Chapter 5.1 --- Identification of a fetal epigenetic marker on chromosome 13 for the detection of fetal trisomy 13 by the epigenetic-genetic (EGG) chromosome dosage approach --- p.98 / Chapter 5.2 --- Experimental design --- p.101 / Chapter 5.3 --- Results --- p.105 / Chapter 5.3.1 --- Optimization of the digestion protocol --- p.105 / Chapter 5.3.2 --- Detection of digestion-resistant EFNB2-3'UTR moleculesin maternal plasma --- p.109 / Chapter 5.3.3 --- Evaluation of the fetal specificity of digestion-resistant EFNB2´ؤ3 'UTR DNA molecules in maternal plasma --- p.111 / Chapter 5.3.4 --- Comparison of EFNB2-3'UTR methylation profiles between the euploid and trisomy 13 placental tissue samples --- p.115 / Chapter 5.3.5 --- Chromosome dosage analysis by the EGG analysis using placental tissue samples --- p.118 / Chapter 5.4 --- Discussion --- p.122 / Chapter SECTION IV: --- CONCLUDING REMARKS --- p.125 / Chapter CHAPTER 6: --- CONCLUSION AND FUTURE PERSPECTIVES --- p.126 / Chapter 6.1 --- Development of fetal epigenetic markers for noninvasive prenatal diagnosis --- p.126 / Chapter 6.2 --- Systematic identification of fetal epigenetic markers on chromosome13 --- p.127 / Chapter 6.3 --- Detection of fetal trisomy 13 by the epigenetic-genetic (EGG) relative chromosome dosage analysis --- p.129 / Chapter 6.4 --- Future perspectives --- p.132 / Appendix I --- p.134 / Appendix II --- p.136 / REFERENCES --- p.142

Errata slip inserted at back / Bibliography: leaves 159-192 / vi, 142, [75] leaves : ill ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Summary: Primary object ... was to construct a pulsed field gel electrophoresis (PFGE) derived long range restriction map of this region by physically linking adjacent DNA probes to common high molecular weight genomic DNA fragments / Thesis (Ph.D.)--University of Adelaide, Dept. of Paediatrics, 1994

Thesis (doctoral)--Göteborg University, 2005. / Includes bibliographical references (p. 438-449) and index.

Thesis (doctoral)--Göteborg University, 2005. / Includes bibliographical references (p. 438-449) and index.